Results 51 to 60 of about 2,353 (181)

The Effect of pncA Gene Mutation of Mycobacterium Tuberculosis to Transaminase and Uric Acid Serum in MDR TB Patient

Jurnal Respirologi Indonesia, 2018
Bacground: The common side effects of PZA treatment is the occurrence of hepatotoxicity and blocking the secretion of uric acid. This study aims to determine the effect of the pncA gene mutation of Mycobacterium tuberculosis to serum transaminase and serum uric acid in patients with MDR TB who had receive therapy with PZA. Methods ...
Yeni Vera, Bintang Yinke Magdalena Sinaga, Dedi Ardinata, Yahwardiah Siregar   +3 more
openalex   +3 more sources

Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study

mBio, 2014
Pyrazinamide (PZA) is a prodrug that is converted to pyrazinoic acid by the enzyme pyrazinamidase, encoded by the pncA gene in Mycobacterium tuberculosis.
Paolo Miotto, Andrea M. Cabibbe, Silke Feuerriegel, Nicola Casali, Francis Drobniewski, Yulia Rodionova, Daiva Bakonyte, Petras Stakenas, Edita Pimkina, Ewa Augustynowicz-Kopeć, Massimo Degano, Alessandro Ambrosi, Sven Hoffner, Mikael Mansjö, Jim Werngren, Sabine Rüsch-Gerdes, Stefan Niemann, Daniela M. Cirillo   +17 more
doaj   +1 more source

Colorimetric methods for rapid determination of pyrazinamide resistance

International Journal of Mycobacteriology, 2020
Background: Because pyrazinamide (PZA) is only effective for Mycobacterium tuberculosis at an acidic pH, susceptibility tests are more difficult to perform than those for other anti-tuberculosis (TB) drugs.
Ahmet Ugur Akbal, Belma Durupinar, Ahmet Yilmaz Coban   +2 more
doaj   +1 more source

Next-generation sequencing to characterise pyrazinamide resistance in Mycobacterium tuberculosis isolates from two Balkan countries

Journal of Global Antimicrobial Resistance, 2022
: Objectives: Next-generation sequencing (NGS) can provide a comprehensive analysis of the genetic alterations most commonly linked with pyrazinamide (PZA) resistance. However, there are no studies reporting the molecular background of PZA resistance in
Eva Sodja, Simon Koren, Nataša Toplak, Sara Truden, Manca Žolnir-Dovč   +4 more
doaj   +1 more source

Exploring of pyrazinamidase recombinant activity from PZA-sensitive and resistant Mycobacterium tuberculosis expressed in Escherichia coli BL21 (DE3) [PDF]

Brazilian Journal of Biology
The mutations of pncA gene encoding pyrazinamidase/PZase in Mycobacterium tuberculosis are often associated with pyrazinamide/PZA resistance. The H and R1 isolates showed significant phenotypic differences to PZA.
P. Purkan, S. Hadi, W. Retnowati, S. Sumarsih, D. K. Wahyuni, B. Piluharto, T. M. Panjaitan, C. Ifada, A. Nadila, B. A. Nabilah   +9 more
doaj   +1 more source

Genetic analysis of pyrazinamide resistance: mutations in the pncA gene among clinical isolates of multi-drug resistant Mycobacterium Tuberculosis [PDF]

Journal of Medical pharmaceutical and allied sciences
Pyrazinamide (PZA) resistance presents a significant challenge in tuberculosis (TB) management, particularly in multi-drug resistant (MDR) cases. Understanding the genetic basis of PZA resistance is crucial for effective treatment strategies. This review provides a comprehensive overview of recent advancements in molecular characterization of PZA ...
A. Tejashree
openalex   +2 more sources

In-depth molecular characterization of Mycobacterium tuberculosis from New Delhi--predominance of drug resistant isolates of the 'modern' (TbD1) type. [PDF]

PLoS ONE, 2009
BACKGROUND: India has the highest estimated burden of tuberculosis in the world, accounting for 21% of all tuberculosis cases world-wide. However, due to lack of systematic analysis using multiple markers the available information on the genomic ...
Ruth Stavrum, Vithal Prasad Myneedu, Virendra K Arora, Niyaz Ahmed, Harleen M S Grewal   +4 more
doaj   +1 more source

Structural and Genomic Insights Into Pyrazinamide Resistance in Mycobacterium tuberculosis Underlie Differences Between Ancient and Modern Lineages

Frontiers in Molecular Biosciences, 2021
Resistance to drugs used to treat tuberculosis disease (TB) continues to remain a public health burden, with missense point mutations in the underlying Mycobacterium tuberculosis bacteria described for nearly all anti-TB drugs.
Tanushree Tunstall, Jody Phelan, Charlotte Eccleston, Taane G. Clark, Taane G. Clark, Nicholas Furnham   +5 more
doaj   +1 more source

Silibinin‐driven microbial and metabolic reprogramming restores CD4+ T cell immunity in HIV immunological nonresponders

VIEW, Volume 6, Issue 6, December 2025.
Despite efficacious antiretroviral therapy, 10%–40% of HIV‐infected individuals exhibit inadequate immune reconstitution due to persistent inflammatory activation and NAD+ metabolic dysregulation—a critical cofactor in cellular bioenergetics. We administered silibinin to 53 HIV immunological non‐responders and elucidated its mechanism through selective
Wenli Liu, Minghui An, Qi Wang, Yuxin Shang, Shuyao Zang, Haibo Ding, Shuai Fu, Yun Liu, Xue Dong, Xiao Yang, Jinna Dai, Xiaoxu Han, Yingchun Xu, Hong Shang   +13 more
wiley   +1 more source

Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia

BMC Infectious Diseases, 2017
Background The ongoing epidemic of multidrug-resistant tuberculosis (MDR-TB) in Georgia highlights the need for more effective control strategies.
Sarah Sengstake, Indra L Bergval, Anja R Schuitema, Jessica L de Beer, Jody Phelan, Rina de Zwaan, Taane G Clark, Dick van Soolingen, Richard M Anthony   +8 more
doaj   +1 more source